Proteasome inhibition and its therapeutic potential in multiple myeloma
Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA; 2New York University School of Medicine, New York, NY, USAAbstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2010-09-01
|
| Series: | Biologics: Targets & Therapy |
| Online Access: | http://www.dovepress.com/proteasome-inhibition-and-its-therapeutic-potential-in-multiple-myelom-a5371 |
| _version_ | 1819000091197833216 |
|---|---|
| author | Ajai Chari Amitabha Mazumder Sundar Jagannath |
| author_facet | Ajai Chari Amitabha Mazumder Sundar Jagannath |
| author_sort | Ajai Chari |
| collection | DOAJ |
| description | Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA; 2New York University School of Medicine, New York, NY, USAAbstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an unprecedented eight years. In the wake of this rapid approval arose a large number of questions about its mechanism of action and toxicity as well as its ultimate role in the treatment of this disease. In this article, we briefly review the preclinical and clinical development of the drug as the underpinning for a systematic review of the large number of clinical trials that are beginning to shed some light on the full therapeutic potential of bortezomib in myeloma. We conclude with our current understanding of the mechanism of action of this agent and a discussion of the novel proteasome inhibitors under development, as it will be progress in these areas that will ultimately determine the true potential of proteasome inhibition in myeloma.Keywords: bortezomib, multiple myeloma |
| first_indexed | 2024-12-20T22:27:48Z |
| format | Article |
| id | doaj.art-bfa5dae794bc4d58b562ef9039d50e04 |
| institution | Directory Open Access Journal |
| issn | 1177-5475 1177-5491 |
| language | English |
| last_indexed | 2024-12-20T22:27:48Z |
| publishDate | 2010-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Biologics: Targets & Therapy |
| spelling | doaj.art-bfa5dae794bc4d58b562ef9039d50e042022-12-21T19:24:47ZengDove Medical PressBiologics: Targets & Therapy1177-54751177-54912010-09-012010default273287Proteasome inhibition and its therapeutic potential in multiple myelomaAjai ChariAmitabha MazumderSundar JagannathAjai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA; 2New York University School of Medicine, New York, NY, USAAbstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA approval in multiple myeloma in an unprecedented eight years. In the wake of this rapid approval arose a large number of questions about its mechanism of action and toxicity as well as its ultimate role in the treatment of this disease. In this article, we briefly review the preclinical and clinical development of the drug as the underpinning for a systematic review of the large number of clinical trials that are beginning to shed some light on the full therapeutic potential of bortezomib in myeloma. We conclude with our current understanding of the mechanism of action of this agent and a discussion of the novel proteasome inhibitors under development, as it will be progress in these areas that will ultimately determine the true potential of proteasome inhibition in myeloma.Keywords: bortezomib, multiple myelomahttp://www.dovepress.com/proteasome-inhibition-and-its-therapeutic-potential-in-multiple-myelom-a5371 |
| spellingShingle | Ajai Chari Amitabha Mazumder Sundar Jagannath Proteasome inhibition and its therapeutic potential in multiple myeloma Biologics: Targets & Therapy |
| title | Proteasome inhibition and its therapeutic potential in multiple myeloma |
| title_full | Proteasome inhibition and its therapeutic potential in multiple myeloma |
| title_fullStr | Proteasome inhibition and its therapeutic potential in multiple myeloma |
| title_full_unstemmed | Proteasome inhibition and its therapeutic potential in multiple myeloma |
| title_short | Proteasome inhibition and its therapeutic potential in multiple myeloma |
| title_sort | proteasome inhibition and its therapeutic potential in multiple myeloma |
| url | http://www.dovepress.com/proteasome-inhibition-and-its-therapeutic-potential-in-multiple-myelom-a5371 |
| work_keys_str_mv | AT ajaichari proteasomeinhibitionanditstherapeuticpotentialinmultiplemyeloma AT amitabhamazumder proteasomeinhibitionanditstherapeuticpotentialinmultiplemyeloma AT sundarjagannath proteasomeinhibitionanditstherapeuticpotentialinmultiplemyeloma |